Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2023 16:01 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

– Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled or resistant hypertension in April 2023 – – Plan to initiate the second pivotal...
May 02, 2023 08:00 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

– Topline data from the trial are expected in the first half of 2024 – – A second, pivotal trial of lorundrostat in uncontrolled and resistant hypertension expected to commence enrollment in the...
May 01, 2023 08:00 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023

RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by...
April 27, 2023 16:47 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023

RADNOR, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by...
March 15, 2023 16:01 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

– Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023 – –IPO and Nasdaq listing completed in February 2023...
March 04, 2023 16:30 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to lorundrostat with...
March 01, 2023 16:05 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023

RADNOR, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by...
February 20, 2023 08:00 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023

RADNOR, Pa., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by...
February 14, 2023 16:01 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

RADNOR, Pa., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by...
February 09, 2023 18:34 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

RADNOR, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by...